InvestSMART

Anatara Lifesciences Ltd (ASX:ANR)

ALERT: Price-sensitive ASX Announcement for ANR
Current share price for ANR : $0.009 -0.003 (-25%)+
Announcement
Release
17 Dec 2025 10:57AM
Price at Release
$0.012
Full Release
download
Summary
Anatara Lifesciences Ltd provided an update on its Anti-Obesity Project, highlighting pre-clinical studies indicating that a candidate compound, 'AOC,' showed significant potential in weight management. The studies, conducted at the University of Newcastle, demonstrated that AOC helps control weight gain and reduce perigonadal fat weight in a mouse model. The Mechanism of Action (MOA) studies faced delays due to a shortage of a specific assay kit but are expected to complete by late January 2026. The outcome of these studies will guide further steps toward product commercialization. The Anti-Obesity Project aims to develop an oral medication to aid weight loss and control rebound weight gain when combined with existing treatments. The company continues to explore additional business opportunities and remains committed to addressing unmet medical needs, particularly in gastrointestinal health with its GaRP product.
Key Points
  • Anatara's Anti-Obesity Project is progressing with positive initial study results.
  • Compound AOC showed significant weight control in pre-clinical trials.
  • Delays in MOA studies due to assay kit availability with completion expected by January 2026.
  • The project aims to develop a complementary oral medication for weight management.
  • Anatara is exploring further business development opportunities.
  • The GaRP project is nearing publication, enhancing its commercial potential in gastrointestinal health.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.